References
- Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study. Front Med (Lausanne). 2021;8:743180.
- Colombo G, Altomare G, Peris K, et al. Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag. 2008;4:559–568.
- Nast A, Gisondi P, Ormerod AD, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris-update 2015-short version-EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29(12):2277–2294.
- Esposti LD, Perrone V, Sangiorgi D, et al. Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies. Biologics. 2018;12:151–158.
- Damiani G, Conic RRZ, de Vita V, et al. When IL-17 inhibitors fail: real-life evidence to switch from secukinumab to Adalimumab or ustekinumab. Dermatol Ther. 2019;32(2):e12793.
- van de Kerkhof PC, Reich K, Kavanaugh A, et al. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey. J Eur Acad Dermatol Venereol. 2015;29:2002–2010.
- Vogler S, Schneider P, Zuba M, et al. Policies to encourage the use of biosimilars in European countries and their potential impact on pharmaceutical expenditure. Front Pharmacol. 2021;12:625296.
- Hercogová J, Papp KA, Chyrok V, et al. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference Adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2020;182(2):316–326.
- Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of the biosimilar ABP 501 compared with Adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2017;177(6):1562–1574.
- Saurat JH, Stingl G, Dubertret L, et al. CHAMPION study investigators. Efficacy and safety results from the randomized controlled comparative study of Adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558–566.
- Blauvelt A, Lacour JP, Jf F Jr, et al. Phase III randomized study of the proposed Adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018;179(3):623–631.
- Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978;157:238–244.
- Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34:2461–2498.
- [cited 2022 Jan 5]. Available from: https://www.gazzettaufficiale.it/eli/id/2018/05/22/18A03476/sg
- cited 2022 Jan 5]. Available from: https://www.gazzettaufficiale.it/eli/id/2018/08/07/18A05194/sg
- cited 2022 Jan 5]. Available from: https://www.gazzettaufficiale.it/atto/serie_generale/caricaArticolo?art.progressivo=0&art.idArticolo=2&art.versione=1&art.codiceRedazionale=19A00797&art.dataPubblicazioneGazzetta=2019-02-09&art.idGruppo=0&art.idSottoArticolo1=10&art.idSottoArticolo=1&art.flagTipoArticolo=0
- cited 2022 Jan 5]. Available from: https://www.gazzettaufficiale.it/eli/id/2020/02/03/20A00685/sg
- cited 2022 Jan 5]. Available from: https://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=2018-05-02&atto.codiceRedazionale=18A02949&elenco30giorni=true
- cited 2022 Jan 5]. Available from: https://www.gazzettaufficiale.it/eli/id/2016/05/13/16A03646/sg
- cited 2022 Jan 5]. Available from: https://www.gazzettaufficiale.it/eli/id/2019/07/08/19A04407/sg
- cited 2022 Jan 5]. Available from: http://azero.veneto.it/public/alboOnline.xhtml?pageType=all
- cited 2022 Mar 5]. Available from: https://www.aopd.veneto.it/all/NOMENCLATORE_TARIFFARIO_REGIONALE_2013.pdf
- Gisondi P, Geat D, Conti A, et al. TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis. Expert Rev Clin Immunol. 2020;16(6):591–598.
- Barker J, Baker H, Nadeem A, et al. Health economic assessment of optimal biological treatment for moderate-to-severe psoriasis. Clin Drug Investig. 2021;41(11):1011–1020.
- Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol. 2013;149:1180–1185.
- Burgos-Pol R, Martínez-Sesmero JM, Ventura-Cerdá JM, et al. The cost of psoriasis and psoriatic arthritis in 5 European countries: a systematic review. Actas Dermosifiliogr. 2016;107(7):577–590.
- Darjani A, Heidarzadeh A, Golchai J, et al. Quality of life in psoriatic patients: a study using the short form-36. Int J Prev Med. 2014;5(9):1146–1152.
- Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383–392.
- Petraskiene R, Valiukeviciene S, Macijauskiene J. Associations of the quality of life and psychoemotional state with sociodemographic factors in patients with psoriasis. Medicina (Kaunas). 2016;52(4):238–243.
- Villacorta R, Teeple A, Lee S, et al. A multinational assessment of work-related productivity loss and indirect costs from a survey of patients with psoriasis. Br J Dermatol. 2020;183(3):548–558.
- Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2020;1(1):CD011535.
- Ozkok Akbulut T, Topaloglu Demir F, Oguz Topal I, et al. Drug survival and predictor factors for discontinuation of methotrexate in psoriasis: a real-life multicenter study. Int J Dermatol. 2021;60(9):1140–1147.
- Mourad AI, Gniadecki R. Biologic drug survival in psoriasis: a systematic review & comparative meta-analysis. Front Med (Lausanne). 2021;7:625755.
- Whiting-O’Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med. 1991;90(6):711–716.
- Mantovani A, Gisondi P, Lonardo A, et al. Relationship between non-alcoholic fatty liver disease and psoriasis: a novel hepato-dermal axis? Int J Mol Sci. 2016;17(2):217.
- Candia R, Ruiz A, Torres-Robles R, et al. Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2015;29(4):656–662.
- Gelfand JM, Wan J, Zhang H, et al. Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: a population-based study. J Am Acad Dermatol. 2021;84(6):1636–1643.
- Gisondi P, Bellinato F, Targher G, et al. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022;81(1):68–73.
- Acosta Felquer ML, LoGiudice L, Galimberti ML, et al. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann Rheum Dis. 2022;81:74–79.
- von Stülpnagel Cc, Augustin M, Düpmann L, et al. Mapping risk factors for cumulative life course impairment in patients with chronic skin diseases - a systematic review. J Eur Acad Dermatol Venereol. 2021;35(11):2166–2184.
- Iversen L, Eidsmo L, Austad J, et al. Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification - rationale and design of the randomized, multicenter STEPIn study. J Eur Acad Dermatol Venereol. 2018;32(11):1930–1939.
- Damiani G, Conic RRZ, Pigatto PDM, et al. Predicting secukinumab fast-responder profile in psoriatic patients: advanced application of Artificial-Neural-Networks (ANNs). J Drugs Dermatol. 2020;19(12):1241–1246.
- Damiani G, Pacifico A, Linder DM, et al. Nanodermatology-based solutions for psoriasis: state-of-the art and future prospects. Dermatol Ther. 2019;32:e13113.